| Quarterly Financials | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 195 | 165 | 250 | 285 | 208 | 271 | 252 | 330 | 228 | 320 | 261 | 439 | 219 |
| Expenses | 116 | 122 | 131 | 146 | 123 | 147 | 135 | 187 | 135 | 177 | 146 | 241 | 143 |
| EBITDA | 79 | 44 | 119 | 139 | 85 | 124 | 117 | 143 | 93 | 144 | 115 | 198 | 77 |
| Operating Profit % | 36 % | 24 % | 46 % | 47 % | 37 % | 44 % | 44 % | 41 % | 38 % | 43 % | 40 % | 44 % | 30 % |
| Depreciation | 14 | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 64 | 30 | 105 | 124 | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 |
| Tax | 15 | 8 | 27 | 32 | 17 | 29 | 26 | 34 | 20 | 35 | 25 | 43 | 15 |
| Net Profit | 49 | 22 | 77 | 92 | 55 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 |
| EPS in ₹ | 4.71 | 2.10 | 7.40 | 8.75 | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 |
Concord Biotech
Concord Biotech
1,604.10
+6.10
(0.38%)
Company has added their latest Presentation1 day ago
Show All
Market Cap
16,717.70 Cr
EPS
35.52
PE Ratio
47.11
Dividend Yield
0.67 %
Industry
Healthcare52 Week High
2,664.00
52 Week Low
1,345.00
PB Ratio
9.25
Debt to Equity
0.01
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
Concord Biotech Limited reported revenue of Rs 204 crores, down 5% year-on-year, attributed to lumpiness in customer procurement patterns. EBITDA fell 24% to Rs 61 crores and PAT decreased 26% to Rs 44 crores, impacted by expenses related to new injectable facility commercialization. However, gross margins improved slightly to 77.9%. The company achieved several operational milestones including successful completion of USFDA, EU GMP, and Russian GMP inspections at its Dholka facility, commencement of commercial CDMO supplies to a US customer, acquisition of 75% stake in US-based Stellon Biotech, and incorporation of wholly-owned subsidiary Concord Lifegen Limited for domestic marketing. Management remains optimistic about growth prospects driven by geographical expansion, new product launches, and CDMO opportunities.
Concord Biotech Limited reported strong financial performance for Q1 FY2026. Income from operations increased to Rs. 24,907.45 lakhs from Rs. 20,100.62 lakhs in Q1 FY2025. Net profit after tax rose to Rs. 3,234.79 lakhs compared to Rs. 2,558.62 lakhs in the previous year. Earnings per share improved to Rs. 2.54 from Rs. 2.02. Total comprehensive income grew significantly to Rs. 4,662.61 lakhs from Rs. 2,652.25 lakhs. The company's equity share capital increased to Rs. 1,274.83 lakhs from Rs. 1,011.58 lakhs. The results were approved by the Board of Directors on August 8, 2025, and published in Financial Express newspapers on August 9, 2025.
Concord Biotech Reports Q1 Results and Declares Rs. 10.70 Dividend Per Share3 days ago
Concord Biotech Limited announced its unaudited financial results for the quarter ended June 30, 2025. On a standalone basis, the company reported revenue from operations of Rs. 20,398.76 lakhs compared to Rs. 21,580.17 lakhs in the same quarter last year. Profit after tax stood at Rs. 4,256.55 lakhs versus Rs. 5,823.86 lakhs in the previous year quarter. Earnings per share was Rs. 4.07 compared to Rs. 5.57 in the corresponding quarter. The board approved a dividend of Rs. 10.70 per equity share with September 3, 2025 set as the record date. The company also made an equity investment of USD 1,500 in Stellon Biotech Inc., USA, acquiring a 75% ownership stake through subscription of 15 million equity shares.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,608.40 | #1 3,80,750.50 | 33.73 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 37.98 | |
5,992.00 | 1,57,011.40 | 68.94 | 9,712.00 | 18.67 | 2,191 | 26.74 | 27.95 | |
3,614.90 | 1,20,933.30 | 60.56 | 11,539.40 | 6.99 | 1,911 | 19.91 | 57.58 | |
1,504.80 | 1,20,009.20 | 22.52 | 28,409.50 | 7.12 | 5,291 | 9.88 | 49.78 | |
2,437.50 | 1,01,824.30 | 53.20 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.00 | |
1,219.50 | 1,01,099.90 | #1 17.91 | 33,741.20 | 16.73 | 5,725 | 1.26 | 40.35 | |
955.55 | 94,198.60 | 20.69 | 23,511.00 | 13.82 | 4,615 | -0.19 | 47.23 | |
1,944.80 | 87,594.20 | 24.03 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 52.40 | |
32,980.00 | 69,793.30 | 49.56 | 6,684.70 | 10.80 | 1,414 | 27.83 | 45.11 | |
1,052.90 | 60,525.30 | 18.19 | 31,378.10 | 17.55 | 3,366 | -10.24 | 35.02 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
18.26 %
Net Income Growth
28.32 %
Cash Flow Change
7.91 %
ROE
8.44 %
ROCE
7.81 %
EBITDA Margin (Avg.)
3.94 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2022 | 2023 | 2024 |
| Total Assets | 941 | 1,313 | 1,514 | 1,701 |
| Fixed Assets | 240 | 573 | 593 | 575 |
| Current Assets | 539 | 633 | 728 | 896 |
| Capital Work in Progress | 141 | 74 | 173 | 212 |
| Investments | 199 | 74 | 137 | 246 |
| Other Assets | 361 | 592 | 611 | 668 |
| Total Liabilities | 941 | 1,313 | 1,514 | 1,701 |
| Current Liabilities | 115 | 155 | 192 | 142 |
| Non Current Liabilities | 55 | 54 | 32 | 32 |
| Total Equity | 770 | 1,103 | 1,290 | 1,527 |
| Reserve & Surplus | 761 | 1,094 | 1,280 | 1,516 |
| Share Capital | 10 | 10 | 11 | 11 |
Cash Flow
| Cash Flow | 2020 | 2022 | 2023 | 2024 |
| Net Cash Flow | -1 | -5 | 3 | 12 |
| Investing Activities | -114 | -112 | -158 | -155 |
| Operating Activities | 155 | 208 | 246 | 266 |
| Financing Activities | -43 | -100 | -85 | -99 |
Share Holding
| % Holding | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % |
| FIIs | 0.00 % | 7.30 % | 0.00 % | 6.48 % | 7.11 % | 8.10 % | 8.33 % | 9.35 % | 9.11 % |
| DIIs | 4.89 % | 8.18 % | 8.13 % | 8.46 % | 10.40 % | 9.89 % | 9.66 % | 9.16 % | 8.87 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.33 % | 6.78 % | 6.76 % | 7.08 % | 7.64 % | 7.33 % | 7.33 % | 6.94 % | 7.43 % |
| Others | 37.69 % | 33.66 % | 41.03 % | 33.90 % | 30.76 % | 30.61 % | 30.59 % | 30.47 % | 30.51 % |
| No of Share Holders | 3,77,572 | 1,00,927 | 87,486 | 83,296 | 80,737 | 84,298 | 82,004 | 81,219 | 82,045 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.83 | 8.75 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.52 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 08 Aug 2025 |  Quarterly Result Announcement | NA | 08 Aug 2025 | 1,739.70 | 1,633.10 |
| 29 May 2025 | Quarterly Result Announcement | NA | 29 May 2025 | 1,532.10 | 1,635.70 |
| 13 Feb 2025 | Quarterly Result Announcement | NA | 13 Feb 2025 | 2,125.70 | 2,119.00 |
| 11 Nov 2024 | Quarterly Result Announcement | NA | 11 Nov 2024 | 1,812.25 | 1,850.00 |
| 29 Jun 2024 |  Annual General Meeting | NA | 29 Jun 2024 | 1,460.10 | 1,549.05 |
| 22 Jun 2024 |  Dividend | ₹ 8.75 /share | 21 Jun 2024 | 1,460.10 | 1,559.25 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
7 hours ago
7 hours agoAnnouncement under Regulation 30 (LODR)-Investor Presentation1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication1 day ago
1 day agoFinancial Results Q1 FY 2025-20263 days ago
3 days agoRecord Date3 days ago
3 days agoBoard Meeting Outcome for Outcome Of Board Meeting3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
6 days agoBoard Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results For The First Quarter Ended On June 30 2025 Along With Limited Review Report7 days ago
7 days agoSuccessful Completion Of Russian GMP InspectionJul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 22, 2025
Jul 22, 2025Successful Completion Of EU GMP InspectionJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 02, 2025
Jul 02, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Update On The USFDA Inspection At The Companys API Facility At DholkaJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 06, 2025
Jun 06, 2025Intimation Pursuant To Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Jun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Appointment Of AuditorsMay 29, 2025
May 29, 2025Appointment of Company Secretary and Compliance OfficerMay 29, 2025
May 29, 2025Corporate Action-Board approves DividendMay 29, 2025
May 29, 2025Financial ResultMay 29, 2025
May 29, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May2025May 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
May 26, 2025Board Meeting Intimation for Approval Of Audited Financial Statements For The Quarter And Year Ended March 31 2025.May 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMay 13, 2025
May 13, 2025Completion Of Inspection By United States Food And Drug Administration (USFDA) Of Our API Facility At Dholka.May 02, 2025
May 02, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Disclosure Under Of SEBI (LODR) Regulations 2015 Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval To Market Teriflunomide Tablets 7 Mg And 14 Mg In The USApr 08, 2025
Apr 08, 2025Commencement Of Commercial Production At Unit-4 ValtheraMar 25, 2025
Mar 25, 2025Closure of Trading WindowMar 22, 2025
Mar 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Mar 10, 2025Board Meeting Outcome for TO Make INVESTMENT IN M/S CLEAN MAX EVERGLADES PVT LTD FOR INSTALLATION OF HYBRID RENEWABLE ENERGY PLANTMar 04, 2025
Mar 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Mar 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 22, 2025
Feb 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 21, 2025
Feb 21, 2025Intimation About Completion Of Inspection By Ministry Of Food And Drug Safety (MFDS) At Dholka (Unit I) Of The Company.Feb 20, 2025
Feb 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Feb 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 14, 2025
Feb 14, 2025Integrated Filing (Financial)Feb 13, 2025
Feb 13, 2025 Financial Results For The Period Ended 31 December 2024Feb 13, 2025
Feb 13, 2025Board Meeting Outcome for Financial Results For The Period Ended 31 December 2024Feb 13, 2025
Feb 13, 2025Technical Indicators
RSI(14)
Neutral 28.10
ATR(14)
Volatile 70.05
STOCH(9,6)
Oversold 10.17
STOCH RSI(14)
Oversold 1.07
MACD(12,26)
Bearish -28.43
ADX(14)
Strong Trend 25.40
UO(9)
Bearish 43.01
ROC(12)
Downtrend But Slowing Down -16.82
WillR(14)
Neutral -75.16
Mutual Fund Holdings
DSP Healthcare Fund Direct - Growth 
Invesco India Smallcap Fund Direct - Growth 
Baroda BNP Paribas Balanced Advantage Fund Direct - Growth 
SBI Healthcare Opportunities Fund Direct Plan-Growth 
Edelweiss Mid Cap Direct Plan-Growth 
UTI Small Cap Fund Direct - Growth 
Union Small Cap Fund Direct-Growth 
Canara Robeco Manufacturing Fund Direct - Growth 
Bandhan Midcap Fund Direct-Growth 
ITI Flexi Cap Fund Direct - Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth About Concord Biotech
Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies products to over 70 countries, including regulated markets like the United States, Europe, and Japan. The company was originally incorporated in 1984, acquired by Sudhir Vaid in 2000, and launched its formulation business in 2016. It went public in August 2023 through an Initial Public Offer.
Listing Date
18 Aug, 2023(1 Years,
25 days)
Chairperson NameSUDHIR JAIRAM VAID
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
